Hypertension (high blood pressure) is a serious risk, being linked to stroke and heart attack as well as other conditions.
About one billion people worldwide are affected by hypertension. The prevalence of essential hypertension increases steadily with age. As the world population ages and preventive strategies in terms of lifestyle changes are so far failing, the prevalence of hypertension is set to increase even further.
Hypertension is a major risk factor for cardiovascular morbidity and mortality. The organs at risk are primarily the heart, the main blood vessels, the brain and the kidneys. The primary goal of any antihypertensive treatment is to prevent cardiovascular events, such as heart attacks or strokes, and finally to reduce cardiovascular mortality. Current evidence suggests that even moderately high blood pressure increases cardiovascular risk and should therefore be treated and targeted with "the lower the better" approach.
Clinical Trial Programmes
The landmark ONTARGET® Trial Programme investigates our long acting angiotensin-receptor blocker Micardis® for cardiovascular outcome: ONgoing Telmisartan Alone and in combination with Ramipiril Global Endpoint Trial - one of the largest angiotensin-receptor blocker trial programmes as part of the ongoing trial programme of Micardis®.
read more
The PRoFESS® (Prevention Regimen For Effectively avoiding Second Strokes) study, another mega-trial, is part of the ongoing trial programme of Micardis®.
read more
An international website provides information on Micardis® and its clinical trial programmes, daily cardiology news and auxiliary tools such as the Braunwald-Atlas of Hypertension.
see website